Assess the following assertion for accuracy/validity - update to include APA citations:

The VIVID and VISTA trials demonstrated Eylea’s ability to improve vision in DME patients with fewer injections required than alternative anti-VEGF agents. The Protocol T clinical trial compared Eylea, Avastin, and Lucentis in DME patients, concluding that Eylea provided superior results in a subgroup of patients with decreased visual acuity (Wells, Glassman, & Ayala et al., 2016).